1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
(
- Contribution to journal › Article
- 2021
-
Mark
Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
(
- Contribution to journal › Article
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article
-
Mark
Data Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
2021) p.63-94(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
(
- Contribution to journal › Article
- 2020
-
Mark
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
(
- Contribution to journal › Article
-
Mark
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
2020) In PLoS ONE(
- Contribution to journal › Article
- 2019
-
Mark
Exposing drug industry funding of UK patient organisations
(
- Contribution to journal › Article
-
Mark
The whistleblowing drama behind Astellas’s suspension from the ABPI
(
- Contribution to journal › Letter
-
Mark
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
(
- Contribution to journal › Article